{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:00:23Z","timestamp":1790258423215,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40261-026-01585-5","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:19:52Z","timestamp":1785331192000},"page":"1161-1174","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Operationalizing Single-Dose Long-Acting Lipoglycopeptides for Treatment of ABSSSI in a U.S. Community Hospital Emergency Department"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3593-4838","authenticated-orcid":false,"given":"Cole","family":"Orlikowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6201-9993","authenticated-orcid":false,"given":"Nicholas","family":"Torney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleah","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Britton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3043-1170","authenticated-orcid":false,"given":"Cynthia","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"1585_CR1","unstructured":"Brown BD, Hood Watson KH. ABSSSI. Statpearls Publishing. 2023. PMID: 31747177."},{"issue":"10","key":"1585_CR2","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1111\/acem.14258","volume":"28","author":"DA Talan","year":"2021","unstructured":"Talan DA, Mower WR, Lovecchio FA, et al. Pathway with single-dose long-acting intravenous antibiotic reduces emergency department hospitalizations of patients with skin infections. Acad Emerg Med. 2021;28(10):1108\u201317. https:\/\/doi.org\/10.1111\/acem.14258.","journal-title":"Acad Emerg Med"},{"issue":"5","key":"1585_CR3","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1080\/21548331.2018.1506673","volume":"46","author":"KR Keyloun","year":"2018","unstructured":"Keyloun KR, Weber DJ, Gardstein BM, et al. Economic burden of hospital admissions for patients with acute bacterial skin and skin structure infections in the United States. Hosp Pract. 2018;46(5):278\u201386. https:\/\/doi.org\/10.1080\/21548331.2018.1506673.","journal-title":"Hosp Pract"},{"issue":"4","key":"1585_CR4","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j\/annemergmed.2018.09.020","volume":"73","author":"WR Mower","year":"2019","unstructured":"Mower WR, Kadera SP, Rodriguez AD, et al. Identification of clinical characteristics associated with high-level care among patients with skin and soft tissue infections. Ann Emerg Med. 2019;73(4):366\u201374. https:\/\/doi.org\/10.1016\/j\/annemergmed.2018.09.020.","journal-title":"Ann Emerg Med"},{"issue":"1","key":"1585_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx188","volume":"5","author":"RS Kamath","year":"2018","unstructured":"Kamath RS, Sudhakar D, Gardner JG. Guidelines vs actual management of skin and soft tissue infections in the emergency department. Open Forum Infect Dis. 2018;5(1):ofx188. https:\/\/doi.org\/10.1093\/ofid\/ofx188.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"1585_CR6","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1093\/cid\/ciu444","volume":"59","author":"DL Stevens","year":"2014","unstructured":"Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissues infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-52. https:\/\/doi.org\/10.1093\/cid\/ciu444.","journal-title":"Clin Infect Dis"},{"issue":"23","key":"1585_CR7","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","volume":"370","author":"HW Boucher","year":"2014","unstructured":"Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169\u201379. https:\/\/doi.org\/10.1056\/NEJMoa1310480.","journal-title":"N Engl J Med"},{"issue":"17","key":"1585_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2147\/TCRM.S271445","volume":"22","author":"O Simonetti","year":"2012","unstructured":"Simonetti O, Rizzetto G, Molinelli E, et al. Review: a safety profile of dalbavancin for on- and off-label utilization. Ther Clin Risk Manage. 2012;22(17):223\u201332. https:\/\/doi.org\/10.2147\/TCRM.S271445.","journal-title":"Ther Clin Risk Manage."},{"key":"1585_CR9","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","volume":"370","author":"RG Corey","year":"2014","unstructured":"Corey RG, Kabler H, Mehra P, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014;370:2180\u201390. https:\/\/doi.org\/10.1056\/NEJMoa1310422.","journal-title":"N Engl J Med"},{"issue":"1","key":"1585_CR10","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/01.ccm.0000626140.51748.aa","volume":"48","author":"A Holyk","year":"2020","unstructured":"Holyk A, McDonald J, Newcomb B, et al. 600: Implementation and evaluation of a dalbavancin protocol for moderate SSSIS in the ED. Crit Care Med. 2020;48(1):280. https:\/\/doi.org\/10.1097\/01.ccm.0000626140.51748.aa.","journal-title":"Crit Care Med"},{"issue":"11","key":"1585_CR11","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1177\/1060028019855159","volume":"53","author":"M Patel","year":"2019","unstructured":"Patel M, Smalley S, Papadopoulos J. Dalbavancin use in the emergency department setting. Ann Pharmacother. 2019;53(11):1093\u2013101. https:\/\/doi.org\/10.1177\/1060028019855159.","journal-title":"Ann Pharmacother"},{"key":"1585_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jgar.2019.02.007","volume":"17","author":"U Rappo","year":"2019","unstructured":"Rappo U, Gonzalez PL, Puttagunta S, et al. Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections. J Glob Antimicrob Resist. 2019;17:60\u20135. https:\/\/doi.org\/10.1016\/j.jgar.2019.02.007.","journal-title":"J Glob Antimicrob Resist"},{"issue":"Suppl 1","key":"1585_CR13","doi-asserted-by":"publisher","first-page":"S491","DOI":"10.1093\/ofid\/ofx163.1265","volume":"4","author":"C Terriff","year":"2017","unstructured":"Terriff C. Transition of care with dalbavancin: a successful cost-saving stewardship program through decreased length of stay. Open Forum Infect Dis. 2017;4(Suppl 1):S491. https:\/\/doi.org\/10.1093\/ofid\/ofx163.1265.","journal-title":"Open Forum Infect Dis"},{"key":"1585_CR14","doi-asserted-by":"publisher","unstructured":"LoVecchio F, McCarthy M, Xiaolan Ye, et al. Single intravenous dalbavancin pathway for the treatment of acute bacterial skin and skin structure infections: considerations for emergency department implementation and cost savings. J Emerg Med. 2024; 67(2): E217-E229. https:\/\/doi.org\/10.1016\/j.jemermed.2024.03.003","DOI":"10.1016\/j.jemermed.2024.03.003"},{"issue":"Suppl 1","key":"1585_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s40801-020-00201-y","volume":"7","author":"B Helton","year":"2020","unstructured":"Helton B, MacWhinnie A, Brooks Minor S, et al. Early directed oritavancin therapy in the emergency department may lead to hospital avoidance compared to standard treatment for acute bacterial skin and skin structure infections: a real-world retrospective analysis. Drugs Real World Outcomes. 2020;7(Suppl 1):20\u20139. https:\/\/doi.org\/10.1007\/s40801-020-00201-y.","journal-title":"Drugs Real World Outcomes"},{"issue":"7","key":"1585_CR16","doi-asserted-by":"publisher","first-page":"e1443","DOI":"10.1093\/cid\/ciaa1730","volume":"73","author":"BP Bookstaver","year":"2021","unstructured":"Bookstaver BP, Milgrom A. Stewarding the costly antibiotic: considerations for dalbavancin. Clin Infect Dis. 2021;73(7):e1443\u20134. https:\/\/doi.org\/10.1093\/cid\/ciaa1730.","journal-title":"Clin Infect Dis"},{"key":"1585_CR17","unstructured":"Dalvance (dalbavancin) for injection, for intravenous use [package insert]. Madison: Allergan USA; 2025."},{"key":"1585_CR18","unstructured":"StataCorp. Stata Statistical Software: Release 18. College Station: StataCorp LLC; 2023."},{"key":"1585_CR19","unstructured":"KFF. Hospital adjusted expenses per inpatient day by ownership: Kaiser Family Foundation. 2020. https:\/\/www.kff.org\/health-costs\/state-indicator\/expenses-per-inpatient-day-byownership\/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D"},{"issue":"2","key":"1585_CR20","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3390\/idr14020032","volume":"14","author":"K Taylor","year":"2022","unstructured":"Taylor K, Williamson J, Luther V, et al. Evaluating the use of dalbavancin for off-label indications. Infect Dis Rep. 2022;14(2):266\u201372. https:\/\/doi.org\/10.3390\/idr14020032.","journal-title":"Infect Dis Rep"},{"key":"1585_CR21","unstructured":"Centers for Medicare & Medicaid Services. Medicare Part B Drug Average Sales Price. CMS.gov. https:\/\/www.cms.gov\/medicare\/payment\/part-b-drugs\/asp-pricing-files. Accessed 12 Aug 2025."},{"issue":"2","key":"1585_CR22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ajem.2019.158442","volume":"38","author":"J Baxa","year":"2019","unstructured":"Baxa J, McCreary E, Shulz L, et al. Finding the niche: an interprofessional approach to defining oritavancin use criteria in the emergency department. Am J Emerg Med. 2019;38(2):321\u20134. https:\/\/doi.org\/10.1016\/j.ajem.2019.158442.","journal-title":"Am J Emerg Med"},{"issue":"9","key":"1585_CR23","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1093\/jac\/dkae177","volume":"79","author":"ZT Wolie","year":"2024","unstructured":"Wolie ZT, Roberts JA, Gilchrist M, et al. Current practices and challenges of outpatient parenteral antimicrobial therapy: a narrative review. J Antimicrob Chemother. 2024;79(9):2083\u2013102. https:\/\/doi.org\/10.1093\/jac\/dkae177.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1585_CR24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3138\/jammi-2024-0015","volume":"10","author":"W Leung","year":"2025","unstructured":"Leung W, Bhalla J, Ataie L, et al. Use of dalbavancin in treatment of acute bacterial skin and skin structure infections: case series from a Canadian perspective. J Assoc Med Microbiol Infect Dis Can. 2025;10(1):40\u201352. https:\/\/doi.org\/10.3138\/jammi-2024-0015.","journal-title":"J Assoc Med Microbiol Infect Dis Can"},{"key":"1585_CR25","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1015\/j.ajem.2022.02.006","volume":"54","author":"A Dolan","year":"2022","unstructured":"Dolan A, Kuge E, Bremmer E, et al. Real world utilization of dalbavancin at a rural community emergency department. Am J Emerg Med. 2022;54:253\u20136. https:\/\/doi.org\/10.1015\/j.ajem.2022.02.006.","journal-title":"Am J Emerg Med"},{"key":"1585_CR26","unstructured":"Lexicomp. Dalbavancin. https:\/\/online.lexi.com. Accessed 4 May 2025."},{"key":"1585_CR27","unstructured":"Lexicomp. Oritavancin. https:\/\/online.lexi.com. Accessed 4 May 2025."},{"key":"1585_CR28","unstructured":"Orbactiv (oritavancin) for injection, for intravenous use [package insert]. Lincolnshire: Melinta Therapeutics, Inc; 2025."},{"key":"1585_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-025-01486-z","author":"K Raja","year":"2025","unstructured":"Raja K, Chen B, Mona P, et al. Budget impact and financial analysis of outpatient dalbavancin in an urban, non-teaching, community hospital. Clin Drug Invest. 2025. https:\/\/doi.org\/10.1007\/s40261-025-01486-z.","journal-title":"Clin Drug Invest"},{"key":"1585_CR30","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jgar.2024.05.020","volume":"38","author":"K Ben-Sassi","year":"2024","unstructured":"Ben-Sassi K, Sarwar S. Impact of first-line dalbavancin for cellulitis on hospital admission and costs: a case series. J Glob Antimicrob Resist. 2024;38:306\u20138. https:\/\/doi.org\/10.1016\/j.jgar.2024.05.020.","journal-title":"J. Glob Antimicrob Resist."},{"issue":"Suppl 1","key":"1585_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf695.968","volume":"13","author":"N Sidik","year":"2026","unstructured":"Sidik N, Bui J, Barrueto F, et al. P-757. Does dalbavancin utilization in the ED reduce hospital admission? Open Forum Infect Dis. 2026;13(Suppl 1):ofaf695.968. https:\/\/doi.org\/10.1093\/ofid\/ofaf695.968.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"1585_CR32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5811\/westjem.2014.11.24133","volume":"16","author":"DA Talan","year":"2014","unstructured":"Talan DA, Salhi BA, Moran GJ, et al. Factors associated with decision to hospitalize emergency department patients with skin and soft tissue infection. West J Emerg Med. 2014;16(1):89\u201397. https:\/\/doi.org\/10.5811\/westjem.2014.11.24133.","journal-title":"West J Emerg Med"},{"key":"1585_CR33","doi-asserted-by":"publisher","unstructured":"Volz AK, Canham L, Kaplan E, et al. Identifying patients with ABSSSI who are likely to require inpatient admission after a stay in an ED observation unit. Am J Emerg Med. 2013;31(2):360\u2013364. https:\/\/doi.org\/10.1016\/j.ajem.2012.09.005","DOI":"10.1016\/j.ajem.2012.09.005"},{"key":"1585_CR34","doi-asserted-by":"publisher","DOI":"10.1177\/10600280251355631","author":"C Orlikowski","year":"2025","unstructured":"Orlikowski C, Dumkow LE, Schmidt KJ, et al. Evaluating risk factors for short versus long hospital stay for cellulitis to guide the development of a long-acting lipoglycopeptide use decision algorithm. Ann Pharmacother. 2025. https:\/\/doi.org\/10.1177\/10600280251355631.","journal-title":"Ann Pharmacother"},{"issue":"Suppl 1","key":"1585_CR35","doi-asserted-by":"publisher","first-page":"S338","DOI":"10.1093\/ofid\/ofx163.804","volume":"4","author":"B Jones","year":"2017","unstructured":"Jones B, Hersey R, Crosby J, et al. Pharmacist-directed use of dalbavancin in acute bacterial skin and skin structure infections to reduce hospital length of stay. Open Forum Infect Dis. 2017;4(Suppl 1):S338. https:\/\/doi.org\/10.1093\/ofid\/ofx163.804.","journal-title":"Open Forum Infect Dis."},{"issue":"Suppl 1","key":"1585_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae631.940","volume":"12","author":"K Weller","year":"2025","unstructured":"Weller K, Bland CM, Jones BM. P-744. Admission avoidance: a protocol for using dalbavancin in the emergency department for acute bacterial skin and skin structure infections. Open Forum Infect Dis. 2025;12(Suppl 1):ofae631.940. https:\/\/doi.org\/10.1093\/ofid\/ofae631.940.","journal-title":"Open Forum Infect Dis."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01585-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01585-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01585-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:13:53Z","timestamp":1790255633000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01585-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1585"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01585-5","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A poster abstract of this data was presented at the 2024 ASHP Midyear Conference (New Orleans, LA) (December 2024), the 24th Annual (2025) Great Lakes Infectious Disease Conference (Grand Rapids, MI) (March 2025), and IDWeek 2025 (Atlanta, GA) (October 2025).","order":2,"name":"Ethics","label":"Previous presentations","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.","order":3,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Munson Healthcare Institutional Review Board (IRB#2257986-1). The study was conducted in accordance with applicable ethical standards and the Declaration of Helsinki.","order":4,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Munson Healthcare Institutional Review Board reviewed the study and granted a waiver of informed consent prior to study initiation (IRB# 2257986-1).","order":5,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Cole Orlikowski: conceptualization, methodology, investigation, and writing. Nicholas Torney: conceptualization, methodology, validation, and writing. Aleah Hunt: methodology, validation, and writing. William Britton: methodology, validation, and writing. Cynthia Nichols: conceptualization, methodology, formal analysis, and writing. All authors read and approved the final version and agree to be accountable for the work.","order":8,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}